Tradestie Institutional Equity Comparison Engine

MESO vs VRDN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VRDN Overall Edge

VRDN Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Viridian Therapeutics, Inc. Common Stock (VRDN) driven by superior Valuation, Momentum & Technical, Options & Structure while MESO counters with relative strength in Growth & Margin. Fundamentally, MESO trades at N/M Forward P/E with -42.6% operating margin (+390.7% YoY revenue) versus VRDN at 1.0x Forward P/E and -1781.4% operating margin (-63.5% YoY). In options structure, MESO sits in UNCLASSIFIED (37th %ile IV; Dealer Gamma Walls on Pro) against VRDN sits in SURGE (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner VRDN
MESO N/M vs VRDN 1.0x Fwd P/E
Growth & Margin Winner MESO
Op Margin -42.6% vs -1781.4% ยท YoY +390.7% vs -63.5%
Momentum & Technical Winner VRDN
1Y -16.4% vs +6.1% ยท 52W Pos 6% vs 81%
Options & Structure Winner VRDN
UNCLASSIFIED (37th %ile IV) vs SURGE (20th %ile IV)
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
1M Return -6.1%
1Y Return -16.42%
Forward P/E N/M
Unified AI Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
VRDN NASDAQ
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$30.22
-2.1% 1D
Market Cap $3.5B
1M Return +58.82%
1Y Return +6.08%
Forward P/E 1.0x
Unified AI Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MESO -16.42% VRDN +6.08% Spread: +22.5 pp (VRDN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MESO TTM Op. Margin: -42.6% VRDN TTM Op. Margin: -1781.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs VRDN. Trailing 12-month operating profitability (MESO -42.6% vs VRDN -1781.4%) and valuation multiples (MESO N/M vs VRDN 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MESO (3) vs VRDN (7)
Institutional Metric MESO VRDN Criterion Row Winner
Market Capitalization Scale $1.7B $3.5B Larger Scale VRDN
Trailing P/E Ratio Valuation N/M 1.0x Lower Multiple VRDN
Forward P/E Ratio Valuation N/M 1.0x Lower Multiple VRDN
Revenue Growth (YoY) Growth +390.7% -63.5% Higher Growth MESO
Operating Margin (TTM) Profitability -42.6% -1781.4% Higher Margin MESO
Net Profit Margin Profitability -47.8% 0.0% Higher Margin VRDN
Return on Equity (ROE) Capital Efficiency -9.9% -83.7% Higher ROE MESO
52-Week Range Position Momentum 6% ($12โ€“$22) 81% ($13โ€“$34) Stronger Trend VRDN
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 78% Vol 1.12ฮฒ ยท 64% Vol Lower Realized Risk VRDN
Unified Institutional Score Composite Signal 34.6 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite VRDN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MESO vs VRDN Buy Guide
MESO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 37th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MESO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VRDN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live VRDN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MESO nor VRDN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.